Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J. Nutt

Showing results (31-40 of 329) with videos related to

Pageof 33
Sort By:
Current Opinion in Pharmacology|January 22, 2005
Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorderKevin C F Fone, David J Nutt
International Journal of Tryptophan Research : IJTR|November 16, 2011
Tryptophan research in panic disorderEduard Maron, Jakov Shlik, David J Nutt
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 26, 2003
Brain imaging studies in human addictsMark R C Daglish, David J Nutt
Hospital Medicine (London, England : 1998)|October 3, 2002
Venlafaxine: a new class of antidepressantJulia Hardy, Spilios Argyropoulos, David J Nutt
Psychopharmacology Bulletin|December 20, 2002
Mechanism of action of antidepressantsFrancesc Artigas, David J Nutt, Richard Shelton
Journal of Psychopharmacology (Oxford, England)|April 24, 2012
Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety?David R Owen, Rainer Rupprecht, David J Nutt
Frontiers in Psychiatry|October 18, 2014
Alcohol and Relatively Pure Cannabis Use, but Not Schizotypy, are Associated with Cognitive AttenuationsDaniela A Herzig, David J Nutt, Christine Mohr
Convulsive Therapy|January 1, 1989
Neuropharmacological Aspects of ECT: In Search of the Primary Mechanism of ActionDavid J. Nutt, Christoph H. Gleiter, Paul Glue
Journal of Psychopharmacology (Oxford, England)|September 1, 2022
Visualizing classification of drugs used in psychotic disorders: A 'subway map' representing mechanisms, established classes and informal categoriesCrystal Zhou, David J Nutt, Simon Jc Davies
Frontiers in Pharmacology|February 2, 2018
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant DepressionLeor Roseman, David J Nutt, Robin L Carhart-Harris
Pageof 33

Showing results (31-40 of 329) with videos related to

Sort By:
Pageof 33
Current Opinion in Pharmacology|January 22, 2005
Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorderKevin C F Fone, David J Nutt
International Journal of Tryptophan Research : IJTR|November 16, 2011
Tryptophan research in panic disorderEduard Maron, Jakov Shlik, David J Nutt
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 26, 2003
Brain imaging studies in human addictsMark R C Daglish, David J Nutt
Hospital Medicine (London, England : 1998)|October 3, 2002
Venlafaxine: a new class of antidepressantJulia Hardy, Spilios Argyropoulos, David J Nutt
Psychopharmacology Bulletin|December 20, 2002
Mechanism of action of antidepressantsFrancesc Artigas, David J Nutt, Richard Shelton
Journal of Psychopharmacology (Oxford, England)|April 24, 2012
Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety?David R Owen, Rainer Rupprecht, David J Nutt
Frontiers in Psychiatry|October 18, 2014
Alcohol and Relatively Pure Cannabis Use, but Not Schizotypy, are Associated with Cognitive AttenuationsDaniela A Herzig, David J Nutt, Christine Mohr
Convulsive Therapy|January 1, 1989
Neuropharmacological Aspects of ECT: In Search of the Primary Mechanism of ActionDavid J. Nutt, Christoph H. Gleiter, Paul Glue
Journal of Psychopharmacology (Oxford, England)|September 1, 2022
Visualizing classification of drugs used in psychotic disorders: A 'subway map' representing mechanisms, established classes and informal categoriesCrystal Zhou, David J Nutt, Simon Jc Davies
Frontiers in Pharmacology|February 2, 2018
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant DepressionLeor Roseman, David J Nutt, Robin L Carhart-Harris
Pageof 33